AFT-70 NAVIGATE will test whether Signatera-guided treatment can reduce unnecessary CDK4/6 inhibitor exposure while ...

Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, ...

A study of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with ...

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journeyclonoSEQ named as an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Measurable residual disease (MRD) is a critical diagnostic tool that predicts disease progression and is increasingly used as an important end point to monitor disease status and evaluate novel ...

A protocolized maintenance de-escalation permitted daratumumab cessation after ≥2 years plus ≥12 months sustained MRD negativity, with most patients not restarting at data cutoff. Generalizability is ...

Dublin, March 19, 2024 (GLOBE NEWSWIRE) -- The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, ...

SAN DIEGO--(BUSINESS WIRE)--Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, has introduced MRDVision, a minimal residual disease (MRD) detection solution showcasing a limit of ...

Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual ...

MRD negativity in MM patients correlates with improved survival, suggesting its potential as a surrogate marker for survival outcomes. Novel therapeutics complicate the assessment of PFS and OS, ...